| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rene Anikwue, John W Huffman, Zachary L Martin, Sandra P Welc. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. The Journal of pharmacology and experimental therapeutics. vol 303. issue 1. 2002-10-21. PMID:12235269. |
our studies with a cannabinoid receptor (cb1) antagonist [n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboximide hydrochloride (sr141716a)], a cb2 antagonist [n-((1s)-endo-1,3,3-trimethyl-bicyclo-heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide) (sr144528)], and an another cb2 agonist [1,1-dimethylbutyl-1-deoxy-delta(9)-thc (jwh-133)] were performed to better characterize ppq interactions with cannabinoid receptors. |
2002-10-21 |
2023-08-12 |
mouse |
| Isabel Matias, Pierre Pochard, Pierangelo Orlando, Michel Salzet, Joel Pestel, Vincenzo Di Marz. Presence and regulation of the endocannabinoid system in human dendritic cells. European journal of biochemistry. vol 269. issue 15. 2002-09-09. PMID:12153574. |
here we have analyzed human dendritic cells for the presence of the endocannabinoids, anandamide and 2-arachidonoylglycerol (2-ag), the cannabinoid cb1 and cb2 receptors, and one of the enzymes mostly responsible for endocannabinoid hydrolysis, the fatty acid amide hydrolase (faah). |
2002-09-09 |
2023-08-12 |
human |
| Robert J McKallip, Catherine Lombard, Michael Fisher, Billy R Martin, Seongho Ryu, Steven Grant, Prakash S Nagarkatti, Mitzi Nagarkatt. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. vol 100. issue 2. 2002-08-30. PMID:12091357. |
targeting cb2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. |
2002-08-30 |
2023-08-12 |
mouse |
| Robert J McKallip, Catherine Lombard, Michael Fisher, Billy R Martin, Seongho Ryu, Steven Grant, Prakash S Nagarkatti, Mitzi Nagarkatt. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. vol 100. issue 2. 2002-08-30. PMID:12091357. |
together, the current data demonstrate that cb2 cannabinoid receptors expressed on malignancies of the immune system may serve as potential targets for the induction of apoptosis. |
2002-08-30 |
2023-08-12 |
mouse |
| N Clayton, F H Marshall, C Bountra, C T O'Shaughness. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. vol 96. issue 3. 2002-08-16. PMID:11972997. |
cb1 and cb2 cannabinoid receptors are implicated in inflammatory pain. |
2002-08-16 |
2023-08-12 |
rat |
| Emmanuel S Onaivi, Claire M Leonard, Hiroki Ishiguro, Ping Wu Zhang, Zhicheng Lin, Babatunde E Akinshola, George R Uh. Endocannabinoids and cannabinoid receptor genetics. Progress in neurobiology. vol 66. issue 5. 2002-08-12. PMID:12015198. |
availability of increasingly-specific cb1 and cb2 cnr antagonists and of cb1 and cb2 cnr knockout mice have increased our understanding of these cannabinoid systems and provides tantalizing evidence for even more g protein-coupled cnrs. |
2002-08-12 |
2023-08-12 |
mouse |
| W Paul Farquhar-Smith, Sian I Jaggar, Andrew S C Ric. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. vol 97. issue 1-2. 2002-08-12. PMID:12031775. |
the use of cannabinoid cb1 receptor (sr141617a) and cb2 receptor (sr144528) antagonists suggested that the effect of anandamide was mediated by both cb1 and cb2 cannabinoid receptors whilst the action of pea was via cb2 (or cb2-like) receptors only. |
2002-08-12 |
2023-08-12 |
Not clear |
| S J Carlisle, F Marciano-Cabral, A Staab, C Ludwick, G A Cabra. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International immunopharmacology. vol 2. issue 1. 2002-07-16. PMID:11789671. |
furthermore, since inflammatory and primed macrophages express the highest levels of cb2, the functional activities of macrophages when in these respective states of activation may be the most sensitive to the action of cannabinoids. |
2002-07-16 |
2023-08-12 |
rat |
| Peter M Zygmunt, David A Andersson, Edward D Hogestat. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 22. issue 11. 2002-07-05. PMID:12040079. |
delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a cb1 and cb2 cannabinoid receptor-independent mechanism. |
2002-07-05 |
2023-08-12 |
mouse |
| Meritxell Alberich Jordà, Sandra E Verbakel, Peter J M Valk, Yolanda V Vankan-Berkhoudt, Mauro Maccarrone, Allessandro Finazzi-Agrò, Bob Löwenberg, Ruud Delwe. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood. vol 99. issue 8. 2002-06-17. PMID:11929767. |
exposure of cb2-expressing cells to different cannabinoids showed that the true ligand for cb2 is 2-arachidonoylglycerol (2-ag), which may act as chemoattractant and as a chemokinetic agent. |
2002-06-17 |
2023-08-12 |
mouse |
| P Valk, S Verbakel, M von Lindern, B Löwenberg, R Delwe. Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2. The hematology journal : the official journal of the European Haematology Association. vol 1. issue 4. 2002-06-10. PMID:11920199. |
anandamide (ana) is an endogenous ligand for the cannabinoid receptors cb1 and cb2 that is able to synergistically stimulate the proliferation of hematopoietic growth factor-dependent blood cells in serum-free culture. |
2002-06-10 |
2023-08-12 |
Not clear |
| L Nong, C Newton, H Friedman, T W Klei. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Advances in experimental medicine and biology. vol 493. 2002-05-20. PMID:11727770. |
marijuana cannabinoid receptors (cbr), cb1 and cb2, are g protein-coupled receptors reported to be expressed in brain as well as cells of the periphery. |
2002-05-20 |
2023-08-12 |
human |
| Francisco Molina-Holgado, Eduardo Molina-Holgado, Carmen Guaza, Nancy J Rothwel. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Journal of neuroscience research. vol 67. issue 6. 2002-04-09. PMID:11891798. |
role of cb1 and cb2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. |
2002-04-09 |
2023-08-12 |
mouse |
| Francisco Molina-Holgado, Eduardo Molina-Holgado, Carmen Guaza, Nancy J Rothwel. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Journal of neuroscience research. vol 67. issue 6. 2002-04-09. PMID:11891798. |
in contrast, coincubation with the cb2 receptor antagonist sr-144528 (1 microm) abolished the inhibitory effects of the endogenous cannabinoid anandamide on lps-induced no release, although this may reflect nonspecific effects of this ligand or cannabinoid actions through atypical receptors of anandamide. |
2002-04-09 |
2023-08-12 |
mouse |
| Claire M Williams, Tim C Kirkha. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology, biochemistry, and behavior. vol 71. issue 1-2. 2002-04-05. PMID:11812541. |
presatiated adult male lister hooded rats received oral administration of the exogenous cannabinoid delta-9-tetrahydrocannabinol (delta(9)-thc; 1.0 mg/kg) in combination with subcutaneous injection of either the cannabinoid cb1 antagonist n-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (sr141716; 0, 0.05, 0.1, 0.5 or 1.0 mg/kg), the cb2 antagonist n-[(1s)-endo-1,3,3-trimethyl bicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (sr144528; 0, 0.05, 0.1, 0.5 or 1.0 mg/kg), the general opioid antagonist naloxone (0.1, 0.5, 1.0 or 5.0 mg/kg) or the 5-ht agonist dexfenfluramine (0.05, 0.1, 0.5, 1.0 or 5.0 mg/kg). |
2002-04-05 |
2023-08-12 |
rat |
| N A Darman. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. European journal of pharmacology. vol 430. issue 1. 2002-01-03. PMID:11698062. |
)-induced vomiting were reversed by nonemetic subcutaneous doses (0, 0.25, 0.5 and 1 mg/kg) of the cannabinoid cb1 receptor antagonist/inverse agonist sr 141716a [n-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] (id50=0.27 and 0.47 mg/kg, respectively) but not by a 5-mg/kg dose of the cannabinoid cb2 receptor antagonist sr 144528 [n-[(1s)-endo-1,3,3-trimethylbicyclo [2.2.1] heptan-2-yl]5-(4-chloro-3-methylphenyl)-1-(4-methybenzyl) pyrazole-3-carboxamide]. |
2002-01-03 |
2023-08-12 |
Not clear |
| W Ponti, T Rubino, M Bardotti, G Poli, D Parolar. Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. Veterinary immunology and immunopathology. vol 82. issue 3-4. 2001-12-17. PMID:11587735. |
both cannabinoid receptors, cb1 and cb2, were involved in this process, since the inhibition was reversed by selective cannabinoid antagonists for both of these receptors. |
2001-12-17 |
2023-08-12 |
human |
| C Bartocci, M G Evandri, P Tucci, P Boll. Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor. Farmaco (Societa chimica italiana : 1989). vol 56. issue 5-7. 2001-12-13. PMID:11482756. |
it has been reported that cannabinoids can inhibit the release of cgrp by stimulation of cb1 and cb2 cannabinoid receptors. |
2001-12-13 |
2023-08-12 |
Not clear |
| Philip T Malan, Mohab M Ibrahim, Hongfeng Deng, Qian Liu, Heriberto P Mata, Todd Vanderah, Frank Porreca, Alexandros Makriyanni. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. vol 93. issue 3. 2001-12-04. PMID:11514083. |
cb2 cannabinoid receptor-mediated peripheral antinociception. |
2001-12-04 |
2023-08-12 |
Not clear |
| A Calignano, G La Rana, D Piomell. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European journal of pharmacology. vol 419. issue 2-3. 2001-11-01. PMID:11426841. |
the antinociceptive effects of palmitylethanolamide were prevented by the cannabinoid cb2 receptor antagonist sr144528 [n-([1s]-endo-1.3.3-trimethylbicyclo[2.3.1]heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide], not by the cannabinoid cb1 receptor antagonist sr141716a [n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide x hcl]. |
2001-11-01 |
2023-08-12 |
mouse |